The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
9 pts

Opinion on  Genentech Inc (DNA)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
A More Focused Highly Defensive Index

Dec 03, 2008 01:32 AM GMT
Mikerun
Return Risk
+1.04% LOW
Principal

A More Focused Highly Defensive Index


The accompanying table [click to enlarge] includes an updated version of the ETF Innovators [ETFI] ETFI Highly Defensive PerformIdex of 36 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. This update includes a 10% reduction in the number of companies with an equal distribution of 12 each from consumer staples and healthcare, with the remaining 12 companies chosen from a variety of defensive industry groups.

(A) Mass Merchant Discount Retailer (1)
(B) Consumer Staples (12) – Non-Food/Beverage (2), Processed & Packaged Foods (3), Tobacco (2) (1 U.S. + 1 ex-U.S.), Alcoholic Beverages (1), Non-Alcoholic Beverages (2), Diversified Products (2)
(C) Telecom Services (4)
(D) Cable Television & Internet Access Providers (1)
(E) Utilities (2)
(F) Fast Food Restaurants (1)
(G) Commodities (2): Gold Mining (1) + Agri-Biotech (Seeds & Fertilizers) (1)
(H) Healthcare (12) – Top Seven Companies by Market Cap (7), Biotech (3) Medical Devices (excluding stents) (1), Generic Drugs (1)
(I) Aerospace (Non-Commercial) & Defense (1)

Over the past year, the index has outpaced its benchmark ETFs on a total return basis with a loss of 16.6%, including the Sabrient/Claymore Defensive ETF (DEF) (-34.6%), Consumer Staples Sector SPDR (XLP) (-18.3%), Healthcare Sector SPDR (XLV) (-31.3%), Utilities Sector SPDR (XLU) (-27.1%), Dow Jones Global Titans (DGT) (-39.7%), and the iShares Dow Jones Select Dividend (DVY) (-35.7%). Also, the equally-weighted defensive index is only 59% as volatile as the overall market with an average market cap of nearly $75B and above-market dividend yield of 3.4%, with a diversified mix of companies and industry groups chosen to outpace benchmark ETFs which focus on a single theme such as dividends, healthcare, or consumer staples.

Among the 36 component companies, I believe Altria Group (MO) and Pfizer (PFE) are defensive dividend, value buys at current levels as each company currently pays a dividend of $1.28 per share annually – resulting in bloated yields of 8.5% and 8%, respectively. Four companies in the index have posted gains on a total return basis (stock price change + dividend yield) over the past year despite unprecedented volatility and major market declines – including a diversified mix of Wal-Mart (WMT), General Mills (GIS), McDonalds (MCD), and Southern Company (SO).

In the healthcare sector, several companies have posted single-digit share price declines over the past year, demonstrating relative strength compared to major losses in the overall market and healthcare sector – including Amgen (AMGN), Genentech (DNA), Gilead Sciences (GILD), Abbott Labs (ABT), and Teva Pharma (TEVA). Among telecom services, AT&T (T), Verizon (VZ), Vodafone (VOD), and Telefonica (TEF) have an average dividend yield over 6%, but this was offset by an average stock price decline of nearly one-third.

Click here for links to my previous articles on defensive investing strategies and indexes or related topics on dividends and healthcare .


DNA:  This call was made on 12/03/08 @ $72.24
Rating:   Positive   $72.24 (12/03/08)
Closed:   01/10/2009 @ $87.25 (+20.78% in 37 days)


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 21.10 +34.44% 381
2 18.14 +71.24% 211
3 17.66 +25.60% 55
4 13.47 +14.32% 62
5 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Genentech Inc (DNA)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
82.5%
Top:
63.5%




Latest Picks by Mike Havrilla
Symbol SP Sentiment Rating Return Since
DNDN Positive -0.22% 11/28/09
UNIFF N/A Positive n/a 11/28/09
CLDA N/A Positive +3.76% 11/26/09
PBIO N/A Positive -9.25% 11/24/09
PUMD N/A Positive n/a 11/23/09

View All >
   
Mike Havrilla previously rated DNA
Positive -13.25% Upcoming FDA Advisory Panel Meetings
03/09/2009
9
Positive +11.70% FDA Decision Calendar: Pain Drug Delays Likely
02/10/2009
9
Positive +0.68% Calendar of 163 FDA Decisions and Clinical Trials
01/21/2009
10
Positive -5.50% Buyout Binge Begins for Bio-Pharma, Diagnostics
01/10/2009
9
Positive -9.36% Updated FDA Calendar of Decision Dates
11/13/2008
9
Positive -6.22% Market Notes: Monday 10-November
11/10/2008
9
Positive +1.81% Healthcare ETFs Outpace the Market
11/01/2008
9
Positive +1.13% Amgen Exceeds Expectations, Again
10/22/2008
9
Positive -2.64% A Defensive Growth Stock Index
10/20/2008
9
Positive -1.35% Discovery Labs: The Next Biotech Winner?
10/06/2008
3





IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch